Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Minnetronix Medical Expands St. Paul. Minnesota, Operations

02/06/2020
Minnetronix Medical, a medical technology company, is expanding its headquarters in St. Paul, Minnesota. The project will receive a $1 million grant and loan from the Department of Employment and Economic Development.

Minnetronix Medical is planning its fourth expansion since moving to St. Paul’s Energy Park Drive in 2000. The 2020 project will increase the company’s footprint from 120,000 square feet to 140,000 square feet, with a plan to grow to 170,000 square feet by 2023. The expansion will accommodate the company’s expected addition of 75 jobs within three years at an average wage of $25.94 an hour.

DEED will assist the project with a $500,000 award from the Job Creation Fund and a $500,000 Minnesota Investment Fund loan. The company’s team of more than 300 employees generates annual revenue of over $100 million.

“Minnetronix Medical embodies Minnesota’s rich history of innovation,” said DEED Commissioner Steve Grove. “DEED’s programs are targeted at companies that are rising leaders in their field and committed to growing good-paying, high-quality jobs in our state.”

“This new Minnetronix investment supported by DEED will support job growth in our Midway Neighborhood,” said Saint Paul Mayor Melvin Carter. “We look forward to supporting Minnetronix’s continued expansion.”

Founded in 1996, Minnetronix has two primary business units. One focuses on the design, development and manufacturing of medical technology specializing in RF energy, fluid and gas management, optical systems and wearable devices. Minnetronix’s second business unit is focused on developing solutions designed to prevent secondary injury and enhance healing for patients hospitalized with life-threatening neurological conditions.

Exclusive Research